Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Share Market News
4 more ASX shares to watch in week 3 of reporting season
Share Market News
Top brokers name 3 ASX shares to sell next week
Coronavirus News
How the coronavirus is impacting these ASX shares
Growth Shares
Is the A2 Milk share price a buy?
⏸️ ASX Shares
Is it time to quit the share market?
Share Market News
ALL ORDINARIES finishes higher Tuesday: 8 ASX shares you missed
Share Fallers
The ASX shares infected by the coronavirus
Share Fallers
Why Beach, Cochlear, Suncorp, & Treasury Wine are tumbling lower
Share Market News
ASX 200 lunch update: Challenger jumps, Cochlear and Suncorp drop
Share Fallers
Cochlear share price down on coronavirus downgrade
Share Market News
Why Macquarie Group is under the spotlight this morning
Share Market News
2 top ASX healthcare shares to buy
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
